Introduction#
Akari Therapeutics Plc has announced that Australia has granted it a patent for its Thailanstatin analog payload technology, which is used in antibody-drug conjugates (ADCs) for cancer treatment. This development comes as the company faces significant challenges, with its market capitalization currently at $6.56 million and shares down nearly 90% over the past year.
Details of the Patent#
The accepted patent, titled "Thailanstatin Analogs," includes claims related to the composition of matter for proprietary analogs designed as cytotoxic ADC therapeutics. These analogs are intended to work with ADC linkers that specifically target proteins found on cancer cells, enhancing the precision of cancer treatments.
Akari’s Pipeline#
Akari’s product pipeline includes two key candidates: AKTX-101, which targets the TROP2 protein, and AKTX-102, which targets CEACAM5. Both of these candidates utilize the PH1 payload, which is protected under the newly granted patent. The company is currently conducting IND-enabling studies for AKTX-101, with plans for a Phase 1 clinical trial expected to begin in late 2026 or early 2027.
Expanding Intellectual Property#
The approval of this patent not only strengthens Akari’s proprietary technology but also broadens its global intellectual property portfolio, which already includes patents in several countries such as the United States, China, and Japan. This expansion is crucial for the company as it seeks to establish a competitive edge in the growing ADC market, projected to reach approximately $12 billion by 2033.
Recent Developments#
In addition to the patent news, Akari has recently presented promising preclinical data for AKTX-101 at a major cancer research conference. The data indicated that AKTX-101 showed significant effectiveness in various cancer cell lines. Furthermore, Akari has formed a strategic partnership with WuXi XDC to expedite the development of its PH1 payload technology, initially focusing on metastatic urothelial cancer.